| Nov 18 |
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
|
| Nov 18 |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
|
| Nov 14 |
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
|
| Nov 13 |
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
|
| Nov 13 |
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
|
| Nov 12 |
Tonix Pharmaceuticals GAAP EPS of -$0.23 beats by $3.65, revenue of $2.82M misses by $0.33M
|
| Nov 5 |
Tonix Pharma Partners for Vaccine Clinical Trial
|
| Nov 4 |
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
|
| Nov 1 |
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
|
| Oct 29 |
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
|
